Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This combination is a multi-ingredient nutraceutical stack primarily utilized in reproductive medicine to improve oocyte quality and ovarian response, particularly in women with diminished ovarian reserve (DOR) or advanced maternal age undergoing assisted reproductive technologies (ART). Coenzyme Q10 (CoQ10) supports mitochondrial function and ATP production within the oocyte, which is critical for spindle assembly and chromosomal segregation. Dehydroepiandrosterone (DHEA) serves as a precursor for follicular steroidogenesis, potentially increasing the number of recruitable follicles and improving the microenvironment of the developing egg. Vitamins C and E act as synergistic antioxidants to mitigate oxidative stress in the follicular fluid, protecting oocytes from reactive oxygen species (ROS). Omega-3 fatty acids (EPA and DHA) provide anti-inflammatory effects, support cellular membrane integrity, and may enhance uterine blood flow. While not a single FDA-approved drug product, this specific combination is frequently studied and recommended by fertility specialists to optimize IVF outcomes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on coenzyme Q10 + dehydroepiandrosterone + vitamin E + vitamin C + omega-3 fatty acids.